Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
VTP-1000 in Adults with Celiac Disease
- Conditions
- Celiac Disease
- Interventions
- Other: Matched Placebo
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Barinthus Biotherapeutics
- Target Recruit Count
- 45
- Registration Number
- NCT06310291
- Locations
- 🇺🇸
Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Centricity Research, Columbus, Ohio, United States
Prime-boost Immunotherapeutic Trial in Men with Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Barinthus Biotherapeutics
- Target Recruit Count
- 22
- Registration Number
- NCT05617040
- Locations
- 🇺🇸
Cornell University, New York, New York, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
Efficacy of VTP-300 in Chronic Hepatitis B Infection
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Barinthus Biotherapeutics
- Target Recruit Count
- 120
- Registration Number
- NCT05343481
- Locations
- ðŸ‡ðŸ‡°
Prince Of Wales Hospital, Hong Kong, Hong Kong
🇨🇳Dalin Tzu Chi Hospital, Chiayi City, Taiwan
🇨🇳Chang Gung Memorial Hospital Kaohsiung, Kaohsiung, Taiwan
First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV
- Conditions
- Hepatitis B
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Barinthus Biotherapeutics
- Target Recruit Count
- 55
- Registration Number
- NCT04778904
- Locations
- 🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷Keimyung University Dongsan Hospital, Daegu, Korea, Republic of
Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions
- Conditions
- HPV InfectionCIN1
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Barinthus Biotherapeutics
- Target Recruit Count
- 108
- Registration Number
- NCT04607850
- Locations
- 🇧🇪
UZA, Antwerp, Belgium
🇧🇪Erasme Hospital, Brussels, Belgium
🇧🇪UZ Brussel, Brussels, Belgium
- Prev
- 1
- 2
- Next
News
Biopharma Job Market Shows Signs of Recovery Despite Continued Layoffs in 2024
Biopharma job postings declined 16% year-over-year in Q4 2024, with at least 24,000 industry professionals laid off throughout the year, including major cuts at Johnson & Johnson, Bristol Myers Squibb, and Bayer.
Imdusiran, VTP-300, and Nivolumab Combination Shows Promise in Chronic Hepatitis B
A Phase 2a trial shows that imdusiran, VTP-300, and low-dose nivolumab led to significantly greater HBsAg declines in chronic hepatitis B patients.